Shots:

• The P-III (DREAMM-8) study assessed the safety & efficacy of Blenrep + pomalidomide & dexamethasone (PomDex) vs bortezomib + PomDex in RRMM patients (n=302) who received at least 1L of therapy or had documented disease progression
• The results showed improved PFS with mPFS not attained vs 12.7mos. at 21.8mos. of median follow-up & 71% vs 51% of patients were alive without progression at the end of 1yr. OS evaluation is underway though a trend was seen during the interim analysis
• Furthermore, the study also demonstrated a 77% vs 72% ORR, 9% vs 3% sCR, 31% vs 14% CR, 24% vs 22% VGPR, 14% vs 34% PR, 40% vs 16% CR or better rate, 64% vs 38% VGPR or better rate & 23.9% vs 4.8% MRD negativity rate with mDoR not reached vs 17.5mos.

Ref: GSK | Image: GSK

Related News:- GSK Reports P-III (DREAMM-8) Study Results of Blenrep for Treating Relapsed/Refractory Multiple Myeloma (RRMM)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com